retatrutide phase 2 results weight loss Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized 2a trial Weight loss with retatrutide as

Prior pancreatitis, gallbladder disease, kidney problems, diabetic retinopathy, significant gastrointestinal symptoms, and use of insulin or sulfonylureas may require closer risk assessment rather than automatic exclusion

A new Blue Health Intelligence (BHI) study based on data from nearly 170,000 commercial health plan members over the past 10 years found that more than 30% of patients dropped out of treatment after the first four weeks, when the dose was still being increased to reach the targeted dose

Unusual new side effect of drugs like Ozempic becoming increasingly common See more of our coverage in your search results

Enhanced Healing: Speeds the repair process of tissues, including skin, bone, and muscle